Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Has Consensus Price Target of $39.50

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been given a consensus rating of “Moderate Buy” by the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $39.50.

A number of research firms recently weighed in on GMAB. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and increased their price target for the company from $32.00 to $43.00 in a research report on Wednesday, July 22nd. Guggenheim boosted their price objective on Genmab A/S from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of Genmab A/S in a research note on Monday, September 14th. New Street Research set a $43.00 target price on shares of Genmab A/S in a report on Wednesday, July 22nd. Finally, Weiss Ratings raised shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research report on Tuesday, September 1st.

Genmab A/S Trading Up 0.6%

Genmab A/S stock opened at $34.75 on Thursday. The firm has a market cap of $21.69 billion, a price-to-earnings ratio of 27.36, a price-to-earnings-growth ratio of 1.89 and a beta of 0.81. Genmab A/S has a 1 year low of $23.62 and a 1 year high of $35.90. The firm’s 50 day moving average price is $32.76 and its two-hundred day moving average price is $28.96. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.17. The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. On average, research analysts predict that Genmab A/S will post 1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new stake in Genmab A/S during the 2nd quarter valued at $31,000. V Square Quantitative Management LLC acquired a new stake in shares of Genmab A/S in the first quarter worth $34,000. MidFirst Bank purchased a new position in shares of Genmab A/S during the fourth quarter valued at $56,000. Nykredit A S purchased a new position in shares of Genmab A/S during the second quarter valued at $58,000. Finally, GAMMA Investing LLC raised its position in Genmab A/S by 16.4% during the second quarter. GAMMA Investing LLC now owns 3,978 shares of the company’s stock valued at $109,000 after buying an additional 561 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes.

Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates.